Trial ID or NCT#

NCT03491683

Status

not recruiting iconNOT RECRUITING

Purpose

Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).

Official Title

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Chirag Patel, MD, PhD
Chirag Patel, MD, PhD
Neuro-oncologist
Clinical Assistant Professor, Neurology & Neurological Sciences Clinical Assistant Professor, Radiology - Rad/Molecular Imaging Program at Stanford
Reena Thomas, MD PhD
Reena Thomas, MD PhD
Neuro-oncologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Seema Nagpal, MD
Seema Nagpal, MD
Neuro-oncologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery

Contact us to find out if this trial is right for you.

CONTACT

Stephanie Lewis
lewisste@stanford.edu